SoftBank raises $4.8 billion from T-Mobile share sale, term sheet shows: Reuters
Japan's SoftBank raised $4.8 billion from a sale of 21.5 million T-Mobile shares at $224 each, according to a term sheet reviewed by Reuters.
The shares were offered in a price range of $224 to $228 each, the term sheet said. The final price was around a 3% discount to T-Mobile's closing price on Monday of $230.99.
SoftBank and T-Mobile did not immediately respond to requests for comment from Reuters.
SoftBank will remain T-Mobile's second largest shareholder after the stock sale, behind Deutsche Telekom which is the U.S. company's biggest investor.
The Japanese firm owned 7.52% of T-Mobile, or 85.36 million shares worth about $22.76 billion, according to LSEG data, ahead of the block trade.
SoftBank said in late 2023 it would receive T-Mobile shares worth about $7.59 billion at no additional cost after conditions set out in an agreement made as part of the merger of SoftBank's U.S. telco Sprint and T-Mobile were met.
Bloomberg News reported the share sale earlier.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
SoftBank Sells T-Mobile Stake for $4.8 Billion to Fund AI Push
(Bloomberg) -- SoftBank Group Corp. raised around $4.8 billion through a sale of T-Mobile US Inc. shares, a move that helps fund the Japanese company's grandiose plans for artificial intelligence. As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space Security Concerns Hit Some of the World's 'Most Livable Cities' As American Architects Gather in Boston, Retrofits Are All the Rage The Tokyo-based technology group sold 21.5 million T-Mobile shares for $224 each — pricing at the bottom of the $224 to $228 range — in an unregistered overnight block sale, according to the final terms of the deal seen by Bloomberg News. The offering — which Bloomberg reported earlier — represents a discount of 3% to T-Mobile US's Monday closing price of $230.99 per share. SoftBank is ramping up investments aimed at making AI reasoning superior to humans': It plans to put down as much as $30 billion in OpenAI and is also working with the ChatGPT creator to ferry hundreds of billions of dollars into data centers and related infrastructure in the US and around the world. Its original plans for debt financing had snagged on uncertainties around US tariffs. T-Mobile shares fell 3.9% in extended trading. They have climbed 4.7% in the year to date through Monday's close. SoftBank's shares climbed as much as 2.3% in early trading in Tokyo. The deal is the biggest US share sale since Toronto-Dominion Bank sold a $13.1 billion stake in brokerage firm Charles Schwab Corp. in February. Sales of new and existing shares in US-listed companies reached $91.4 billion in the year to date, up from $75.9 billion in the same period a year ago, data compiled by Bloomberg show. The T-Mobile stake sale would be the latest example of SoftBank founder Masayoshi Son tapping past investment successes — such as an early bet on Alibaba Group Holding Ltd. that's yielded thousands-fold returns — to fund new ventures. SoftBank received T-Mobile shares with the completion of the US telecom company's $26.5 billion acquisition of Sprint Corp. in April 2020. Later that year, SoftBank substantially reduced its stake in T-Mobile via a $21 billion deal that helped pay for a record buyback of SoftBank's shares. The stake offered represents about 1.9% of T-Mobile's outstanding shares, according to Bloomberg calculations. SoftBank owned 85.4 million shares or 7.5% of T-Mobile as of March 31, according to its annual report. Deutsche Telekom AG is T-Mobile's largest shareholder with a 59% stake, according to a June 12 filing with the US Securities and Exchange Commission. Bank of America Corp. was sole bookrunner for the deal, the terms show. --With assistance from Min Jeong Lee. (Updates share reaction and adds background from the first paragraph.) Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros American Mid: Hampton Inn's Good-Enough Formula for World Domination How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants The Spying Scandal Rocking the World of HR Software US Allies and Adversaries Are Dodging Trump's Tariff Threats ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
2 hours ago
Oil prices rise, US futures fall as Israel urges Tehran residents to evacuate
BANGKOK -- Oil prices resumed their upward climb and U.S. futures were lower early Tuesday after Israel's military issued an evacuation warning to 330,000 people in Iran's capital Tehran. Asian shares were mixed. The evacuation warning was for a part of Tehran, a city of 9.5 million, that houses the country's state TV and police headquarters and three large hospitals, including one owned by Iran's paramilitary Revolutionary Guard. U.S. President Donald Trump announced he was returning from the G7 summit in Canada a day early due to the intensifying conflict. The futures for the S&P 500 and the Dow Jones Industrial Average were down 0.3%. In Asia, Tokyo's Nikkei 225 index climbing 0.6% to 38,547.56 as the Japanese central bank opted to keep its key interest rate unchanged at 0.5%. The Bank of Japan has been gradually raising its rate from near zero and cutting back on its purchases of Japanese government bonds and other assets to help counter inflation. It said economic growth was likely to moderate and there was some weakness in consumer sentiment, housing investment. 'In particular, it is extremely uncertain how trade and policies in each jurisdiction will evolve and how overseas activity and prices will react to them,' the BOJ's statement said. Chinese shares edged lower. In Hong Kong, the Hang Seng slipped 0.1% to 24,038.56. The Shanghai Composite index declined 0.2% to 3,382.14. In South Korea, the Kospi gained 0.4% to 2,956.88. Australia's S&P/ASX 500 gave up 0.1% to 8,543.60. Taiwan's Taiex gained 0.6% and in Bangkok the SET was little changed. As Israel and Iran attack each other the fear remains that a wider war could constrict the flow of Iran's oil to its customers. That in turn could raise gasoline prices worldwide and keep them high, though spikes in prices from previous conflicts have been brief. Crude jumped 7% late last week after Israel's attack on Iranian nuclear and military targets. Early Tuesday, U.S. benchmark crude oil gained 31 cents to $72.08 per barrel, while Brent crude, the international standard, was up 33 cents at $73.56 per barrel. On Monday, the mood was calm on Wall Street, as the S&P 500 climbed 0.9% to reclaim most of its drop from Friday. It closed at 6,033.11. The Dow Jones Industrial Average added 0.8% to 42,515.09, and the Nasdaq composite gained 1.5% to 19,701.21. U.S. Steel rose 5.1% after Trump signed an executive order on Friday paving the way for an investment in the company by Japan's Nippon Steel. Trump would have unique influence over the operations of U.S. Steel under the terms of the deal. They helped offset drops for defense contractors, which gave back some of their jumps from Friday. Lockheed Martin fell 4%, and Northrop Grumman sank 3.7%. The price of gold receded after jumping on Friday, when investors were looking for someplace safe to park their cash. An ounce of gold fell $14.60 to $3,402.40 per ounce. Investors have other concerns, key among them Donald Trump's tariffs, which still threaten to slow the U.S. economy and raise inflation if Washington doesn't win trade deals with other countries. The specter of tariffs was looming over the meeting of the Group of Seven meeting of major economies in Canada. Later this week, the Federal Reserve is set to discuss whether to lower or raise interest rates, with the decision due on Wednesday. The nearly unanimous expectation among traders and economists is that the Fed will stand pat. The Federal Reserve has hesitated to lower interest rates after one cut late last year. It is waiting to see how much Trump's tariffs will hurt the economy and raise inflation, which has remained tame recently, and is near the Fed's 2% target. More important for financial markets on Wednesday will likely be forecasts for where Fed officials they see the economy and interest rates heading in upcoming years. In other dealings early Tuesday, the U.S. dollar fell to 144.59 Japanese yen from 144.75 yen. The euro rose to $1.1564 from $1.1562.
Yahoo
3 hours ago
- Yahoo
Hemogenyx Pharmaceuticals PLC Announces Clearance to Proceed with Pediatric Expansion
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Regulatory Clearance to Proceed with Pediatric Expansion of HG-CT-1 Clinical Trial LONDON, UK / / June 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that the 30-day review period by the U.S. Food and Drug Administration (FDA) for the Company's previously submitted amendment to the clinical protocol of its ongoing Phase I trial of HG-CT-1 has concluded without a clinical hold. As a result, the Company is now cleared to proceed with the next steps required to initiate pediatric enrolment in the trial. The protocol amendment expands the eligibility criteria for the Phase I trial of HG-CT-1, Hemogenyx's proprietary CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML), to include children and adolescents with this aggressive and hard-to-treat disease. The Company will now move forward with Institutional Review Board (IRB) submissions and associated site activation procedures to enable the opening of pediatric cohorts. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"Regulatory clearance to proceed with the pediatric expansion of our HG-CT-1 clinical trial is a significant milestone. It reflects continued momentum in our development program and underscores our commitment to delivering innovative therapies to patients across age groups. This expansion broadens the potential impact and value of HG-CT-1 as we continue to advance toward key inflection points in the clinic. Importantly, it also reinforces the value of Company's robust intellectual property portfolio, which underpins our pipeline and supports long-term strategic growth." The Company will update the market as further progress is made in pediatric site activation and patient enrolment. Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Enquiries: Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@ Peter Redmond, Director SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Hemogenyx Pharmaceuticals PLC View the original press release on ACCESS Newswire
